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ABSTRACT
WITHAFERIN A SYNERGISTICALLY ENHANCES THE EFFECT OF
PACLITAXEL AGAINST LUNG CANCER
Al Hassan Kyakulaga
February 09, 2017
Lung cancer is the leading cause of cancer-related deaths among
both men and women in the U.S and worldwide. Today, paclitaxel (PAC) or taxol
alongside platinum-based drugs is the most widely used agent as first-line regimen
for advanced NSCLC. However, due to toxicity, drug resistance, solubility and
efficacy issues, efficacy has plateaued. In the present study, the potential of a
novel plant-derived steroidal-lactone, withaferin A (WFA), for clinical use alongside
PAC to improve efficacy against NSCLC was explored. The anticancer effects of
PAC and WFA alone, and in combination against the in vitro cell proliferation, cell
adhesion, migration and invasion of two human NSCLC cell lines, H1299 and A549
were determined. Our data shows that PAC and WFA, combined at 1:25 and 1:50
ratios, respectively, synergistically inhibited the proliferation of H1299 and A549
cells. Furthermore, the combination also significantly inhibited the TGFβ1-induced
EMT, cell adhesion, migration, and invasion (p<0.05) indicating a potential antimetastatic activity. Together, if these findings can be replicated in appropriate
animal models, they highlight the potential clinical efficacy of WFA alongside PAC
that can be exploited to improve clinical outcomes of NSCLC treatment.
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INTRODUCTION
Lung cancer has an extremely low survival rate and is currently the leading
cause of cancer-related deaths worldwide and in the US [1-3]. It is estimated that
(see Figure 1) over 1.8 million new cases and 1.6 million deaths occur worldwide
annually [2] of which an estimated 221,200 cases and 158,040 deaths occur in the
U.S [3, 4]. Despite the recent advances in imaging and molecular diagnostic
techniques, targeted therapies and immune checkpoint inhibitors, the overall 5year survival rate for lung cancer has remained less than 17%. Overall more
people die from lung cancer than from breast, prostate, pancreatic and colon
cancers combined [3].
This extremely poor prognosis of lung cancer is explained in part because,
in the early stages, lung cancer is not associated with any major clinical symptoms
[5]. Consequently, the majority (60-70%) of patients are diagnosed when the
disease is in its late stages [2] and is associated with regional and/or distant
metastases for which surgery and radiation are almost impossible [6]. Even among
patients with sufficiently localized tumors, more than half of them have additional
cardiac or pulmonary diseases that complicate the therapeutic options.
Furthermore, it is widely reported that 50-60% of patients who undergo initial
successful surgical resection of primary tumors relapse within 6-12 months [7].
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Together, the advanced stage of lung cancer among most patients, high relapse
rates, tumor cell heterogeneity, biological aggressiveness and intrinsic resistance
to chemotherapy make lung cancer very challenging to treat.
Clinically, lung cancer is not a single disease but refers to a heterogeneous
group of tumors that originate from the lung tissue [5]. These tumors almost
exclusively (>99%) develop from epithelial cells lining the airways, and as such are
also called lung carcinomas [5, 8]. Their carcinogenesis is complex, but multiple
lines of evidence suggest that normal airway epithelial cells are transformed into
lung carcinomas via a multistep carcinogenic process involving the interaction of
genetic, environmental and lifestyle factors [3, 9, 10]. It is hypothesized that
exposure to carcinogens causes specific genetic and/or epigenetic alterations that
confer a proliferative advantage to a small number of cells. Later, these cells get
progressively transformed into biologically aggressive and highly malignant tumors
that are associated with extremely poor prognosis and high mortality rates [5].
Based on cellular morphology, lung cancer is classified as either small-cell
lung cancer (SCLC) or non-small-cell lung cancer (NSCLC) [11]. Current statistics
indicate that only 10-13% of the cases are SCLC while the majority (80-85%) are
NSCLC [5, 12]. SCLC tumors (Figure 2F) are reported to primarily occur among
heavy smokers, and they are histologically identified as small round-shaped cells,
with visible mitotic patterns, granular nuclear chromatin and absent nucleoli [10].
On the other hand, NSCLC tumors are more prevalent among non-smokers and
are further sub-divided into three major subtypes: adenocarcinoma, squamous cell
carcinoma and large cell lung cancer [5, 13, 14]. The adenocarcinomas are
2

currently the most prevalent subtype of NSCLC especially among non-smokers
and women [2, 10]. Histologically, adenocarcinomas (Figure 2A-C) are the NSCLC
tumor cells that appear microscopically as either glandular or mucin-producing cell,
and are usually arranged as acinar, papillary, bronchoalveolar, solid or a mixture
of these growth patterns. In contrast, squamous cell carcinomas which are the
second most prevalent subtype of NSCLC tumors are identified as NSCLC tumor
cells that display intercellular bridges and keratin (Figure 2D). The large-cell
carcinomas (Figure 2E) present as large NSCLC tumor cells that contain vesicular
nuclei and prominent nucleoli. Worldwide, these traditional classifications have
been widely utilized in decision making for treatment strategies for lung cancer.
Unfortunately, in the current era of precision and personalized medicine
[14], the histologic classifications of NSCLC are somewhat insufficient and may
not reflect the underlying driver mutations. Therefore, today NSCLC tumors are
also subtyped using immunohistochemical and molecular techniques to reflect the
genetic mutations that drive and maintain tumorigenesis [15]. Many clinical reports
indicate that adenocarcinomas are usually associated with mutations in the EGFR,
KRAS, and ALK genes [2, 10, 16]. On the other hand, squamous-cell carcinomas
have mutations in SOX2, FGFR1, TP53 and DDR2 genes while small-cell lung
cancers display RB1, TP53 mutations [16]. These molecular classifications allow
for effective and tailored treatments for specific subsets of patients [14, 17].
The causes of lung cancer remain elusive but several risk factors have been
identified in epidemiological studies. To date, cigarette smoking remains the major
cause of lung cancer and the global patterns of lung cancer incidence closely
3

reflect the consumption rates of tobacco products in many countries [5]. In the U.S,
more than half of the newly diagnosed lung cancer cases are directly attributable
to smoking and it is estimated that over 90 million people are at risk of smokingrelated lung cancer [1]. Data from several epidemiological studies indicate that the
risk of lung cancer increases with both quantity and duration of smoking, and is
highest among those who smoke and never quit [3, 5, 10, 15]. Furthermore,
evidence has also increased indicating that side-stream cigarette smoke exposure
or the so-called “passive smoking” also increases the risk of lung cancer and
accounts for a large fraction of lung cancer among non-smokers [2]. Interestingly,
despite the widespread anti-smoking campaigns and the observed declines in
smoking rates in developed countries, the incidence and mortality rates of lung
cancer have only moderately decreased. The American Cancer Society (ACS) has
estimated that the incidence of lung cancer decreased by only 2% among men and
1% among women per year between 2004 and 2013 [3].
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Figure 1. The worldwide estimated global number of new cases and deaths with proportions by
major world regions for lung cancer. (Source: Stewart B.W. and Wild P.S: World Cancer Report,
2014).
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Figure 2. Histologic classifications of lung cancer: (A) acinar adenocarcinoma, (B) papillary
adenocarcinoma (C) invasive mucinous adenocarcinoma (D) squamous-cell carcinoma (E) largecell carcinoma and (F) small-cell carcinoma (Source: Stewart B.W. and Wild P.S (2014). World
Cancer Report, 2014).
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Today, the therapeutic options and clinical outcomes of lung cancer
treatment are highly dependent on the stage of the disease at the time of diagnosis
[6, 13, 18]. Initially, a proper and accurate diagnosis is done to consider the size
and location of the primary tumor, as well as the presence of regional and/or distant
metastases. Later, the data obtained from the initial screening is used to stage the
lung cancer and to select the suitable therapeutic options for each patient [2]. The
World Health Organization (WHO) utilizes and recommends the Tumor-NodeMetastasis (TNM) staging system of lung cancer based on the size of the primary
tumor(T), regional lymph nodes (N), and (M) distant metastases [19, 20]. Using
this system, a combination of TNM descriptors is used to group lung tumors into
seven stages that reflect expected survival outcomes [11].
The seven clinical stages of lung cancer used the world over are; IA, IB, IIA,
IIB, IIIA, IIIB and V. Here, the best therapeutic outcomes expected from stage I
and the worst outcome from stage V [19]. Many clinical reports indicate that the
stages IA, IB, IIA, IIB are considered early stage lung cancer [20, 21] where the
primary tumors are sufficiently localized and therefore are considered curable.
However, patients with stages III-V are considered to have advanced lung cancer
and thus have the worst clinical outcome [20]. The dismal survival for patients with
advanced lung cancer is mainly because of the regional and distant metastases.
Following lung cancer staging, the therapeutic strategies for NSCLC may
include surgery, chemotherapy, and radiation either alone or in combination [6,
13]. The ultimate choice of any one of these treatment options is based on whether
the clinical goal is cure or palliation. For patients with early stage NSCLC (stage I7

II), surgical removal of tumors is the treatment of choice, for which cure is
attainable in up to 80% and 50% for stage I and stage II cases, respectively [13].
However, even with improved diagnostic techniques, only 25% of lung cancer
patients are diagnosed with stage I and stage II of the disease [2]. Moreover, a
majority (50-60%) of the patients that present with early-stage lung cancer also
have impaired pulmonary and cardiac functions which make them ineligible for
surgery because of possible postoperative complications [6].
In contrast, about 35% and 40% of lung cancer patients are diagnosed with
stage III and stage IV lung cancer, respectively [2]. Among these patients, the
primary tumor is already spread beyond the lung tissue into lymph nodes (stage
III) and sometimes with distant metastases (stage IV). Very frequently, advanced
lung cancer patients also have undetected systemic micrometastases that can
result in tumor relapse [13, 18, 22]. Therefore, the main clinical goal of treatment
in advanced lung cancer is palliation of symptoms and to prolong the life of
patients. Because surgery is virtually impractical, either chemotherapy or targeted
therapy, alone or in combination are the viable options [18, 23].
Currently, the platinum-based chemotherapies consisting of either cisplatin
or carboplatin are the first-line drugs for the treatment of advanced NSCLC [6].
Usually, these platinum drugs are administered in combination with a thirdgeneration chemotherapeutic drug like paclitaxel, docetaxel, or vinorelbine [18,
23]. Several published studies and clinical reports indicate that the various drug
combinations of platinum drugs and other chemotherapeutics show similar clinical
efficacy but distinct toxicities [6, 24]. However, a two-drug combination of
8

carboplatin and paclitaxel is the most widely used standard chemotherapeutic
regimen for stage IIIB-IV lung cancer with 1-year survival rate exceeding 40% [4,
24]. Unfortunately, the survival efficacy of the platinum-paclitaxel combination
seems to have reached a survival plateau of about 10 to 11 months and thus a
three-drug combination is now recommended [24]. More recently, because of the
lower toxicity profile of gemcitabine, a three-drug combination consisting of
carboplatin, paclitaxel, and gemcitabine was introduced with promising but minimal
results [24]. In other clinical reports, pemetrexed, a more specific cytotoxic agent
is recommended as the third drug to the cisplatin-paclitaxel combination with
survival rates between 13-14 months [6].
In the past decade or so, there has been considerable progress in
understanding the biology of lung and other cancers [17]. This led to the discovery
of molecular mutations that drive the progression of cancers and subsequently the
introduction of targeted therapies into clinical practice [14, 25]. These targeted
therapies interact with specific molecular drivers involved in carcinogenesis, cell
proliferation, apoptosis, and metastasis of cancer cells. Several reports indicate
that the most promising agents for lung cancer are those agents targeting receptor
tyrosine kinases (RTKs), mitogen-activated protein kinases (MAPKs) and Janus
kinase (JNK) pathways [4, 14, 17]. Indeed, agents targeting EGFR mutations
(erlotinib and gefitinib), ALK gene rearrangements (crizotinib and ceritinib), HER2
mutations (trastuzumab) and angiogenesis (bevacizumab) are currently approved
as targeted therapies for NSCLC [17, 25, 26]. Furthermore, the anti-EGFR agent
erlotinib is also approved by FDA as second-line agents for relapsed lung cancer.
9

Unfortunately, many patients who undergo targeted therapy eventually develop
resistance with continued drug administration and relapse within 4-6 months [17].
Initially, patients show a favorable response to the targeted therapies but it has
been found out that the prolonged administration results into secondary mutations
that cause decreased binding affinity of the drugs to targets. Therefore, even with
targeted therapies, only modest (14-17 months) improvement in overall survival
has been observed and drug resistance is becoming a major problem [6].
The other landmark in NSCLC treatment is the manipulation of the immune
system to enable the body clear tumor cells [27, 28]. This exciting discovery has
been fueled by the increasing body of knowledge on tumor microenvironment and
its interplay with the immune system. Today, immunotherapy is also being
explored as an alternative treatment modality for lung cancer. Unlike
chemotherapy, immunotherapies indirectly target NSCLC tumor by stimulating the
individual’s immune system [6]. Currently, two immunotherapeutic approaches are
utilized, namely, the vaccination and the immune-checkpoint approaches. The
vaccination approach employs either antigens or cells to stimulate T-cells to
eliminate tumors while the immune-checkpoint approach uses specific monoclonal
antibodies to neutralize specific tumor molecular pathways [4, 14]. Vaccines
against EGF, TGFβ, and PD-1 are at different stages of advanced clinical testing
with promising findings [4]. However, even with immunotherapies, the overall 5year survival from lung cancer has continually stagnated between 15-17%
worldwide.
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Therefore, despite the enormous gains from chemotherapies, targeted, and
immunotherapies for many cancer types, the overall gain for lung cancer has been
minimal. To address this therapeutic challenge, there has been a re-awakened
interest in the search for effective therapies for lung cancer from natural sources
including medicinal plants, marine organisms, and microorganisms [28]. In this
quest, medicinal plants have attracted significant attention because of the chemical
and biological diversity of secondary metabolites represent an inexhaustible
source of anticancer compounds. So far, more than 3000 plant species have been
used to treat cancer and many more are under investigation. Generally, these
plant-derived compounds are cost effective, abundantly available and largely nontoxic [4]. More importantly, unlike current drugs, recent evidence from preclinical
and some clinical studies indicates that most plant-derived compounds target
multiple pathways in the cancer cells [29].
Some of the most promising plant-derived compounds include resveratrol,
epigallocatechin 3 gallate (EGCG), curcumin, apigenin, luteolin, barbamine and
withaferin A (WFA) [29-31]. The Gupta lab group at the University of Louisville,
among other projects, is focused on developing WFA into a useful therapeutic
agent for the management of lung cancer. Building on hypotheses based on
previous findings in this and other laboratories, WFA has shown excellent efficacy
and potency against various cancers – lung [32-34], cervical [35], prostate [36],
breast [37-39], ovarian [40] and pancreatic in vitro and in vivo. In the present study,
a simple but effective strategy of combining WFA with paclitaxel against the
proliferation, migration, and invasion of two human NSCLC cells was explored.
11

WFA is a member of the withanolides, a large group of naturally occurring
28-carbon-containing compounds [41]. Chemically, these withanolides (Figure 3B)
are composed of a steroidal framework attached to a lactone ring and as a result,
are sometimes referred to as ‘steroidal-lactones’ [42]. The steroidal part consists
of 4-cycloalkane rings, 3-cyclohexane rings, and 1-cyclopentane ring. The second
part, the lactone ring, is a cyclic ester which is oxidized appropriately to form a 6membered ring [41]. This overall chemical structure can be modified either in the
steroid framework or the side chains yielding a diversity of compounds.
To date, more than 300 different naturally occurring withanolides with
diverse chemical and biological activities have been isolated and characterized
from the Solanaceae plant species [43]. Of all these, WFA [4β, 27-dihydroxy-1oxo-5β, 6β-epoxywitha-2, 24-dienolide], was the first member to be discovered and
is currently the most extensively studied and characterized [42, 44-46]. Initially, it
was first isolated from the leaves of Withania somnifera (Figure 3A) in the 1960s,
and its structure was chemically elucidated shortly thereafter [42, 45, 46]. At that
time, the basic extraction of WFA from the dried W. somnifera material was
accomplished using methanol followed by purification with C-18 and Sefadex
columns [45]. Later, WFA was also extracted from other plants including Withania
aristata, Dunalia spinose and Vassobia breviflora [43, 46]. Because of the multiple
reports on the anticancer activity of WFA, significant efforts are now being directed
towards the chemical synthesis and modification of WFA [47].
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Figure 3. (A) W. somnifera (B) withanolide structure and (C) withaferin A [48, 49].
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In the WFA chemical structure, the basic steroidal framework is ergostane,
to which a lactone ring is attached (Figure 3C). As is the case for the structures of
most withanolides, the lactone in WFA is a cyclic ester composed of 5-carbon
atoms, which in the case of WFA, the carbon atoms at C-22 and C-26 are oxidized
to form a 6-membered ring [50]. This arrangement of atoms in WFA results into
five functional groups including the unsaturated ketone ring, a hydroxyl group at
C-4, epoxide ring between C-5 and C-6, a hydroxyl group at C-27, a 6-carbon
lactone ring, and an unsaturated carbonyl group [47, 48]. Together, these chemical
functional groups account for the diverse biological activities of WFA and each may
be exploited for chemical modification.
Because of its ability to interact with many molecular targets, several
pharmacological activities of WFA have been identified and reported [44, 51].
These biological activities include anti-inflammatory, anticancer, antiangiogenic,
cardioprotective,

immunomodulatory,

hepatoprotective,

anticonvulsant

and

anabolic effects [43, 51]. However, in the past decade or so, WFA has attracted
significant attention and testing mainly for its anticancer activity [44]. There is quite
a plethora of data indicating the anticancer efficacy of WFA from cell culture to
xenograft and orthotopic tumor models of multiple human cancers [44, 48, 51, 52].
In most of the published preclinical studies, it is reported that the observed
anticancer activities of WFA result from its interaction with specific biochemical and
molecular targets like enzymes, signaling molecules and other proteins in cancer
cells [41, 51]. Three positions on the WFA structure have been identified to react
with sulfhydryl groups of cysteine residues in proteins in cancer cells [47]. These
14

positions include the unsaturated ketone (C-3) in the A-ring, the epoxide group at
C-5 and the lactone ring [47]. Recent spectral analysis has revealed that C-3 is the
main target for thiol group binding in the unsaturated A-ring [39]. It is hypothesized
that the sulfhydryl groups of cysteine residues react with C-3 via Michael-Addition
alkylation type of reactions forming covalent bonds with proteins [48, 49].
Furthermore, the epoxide ring between C-5 and C-6 has been reported as the most
critical for its anticancer properties of WFA. To support this hypothesis, an in vitro
study investigating the reaction of WFA and 2-mercaptaethanol, which specifically
affects the 5b,6b-epoxide structure, have reported a loss of anticancer activity. In
the same study, incubation of WFA with strong reducing agents like N-acetyl
cysteine or DTT resulted into loss of the pro-apoptotic activity of WFA [53]. On the
other hand, loss of unsaturation in the A-ring have been reported to cause loss of
anti-inflammatory and antiangiogenic effects of WFA [43, 54].
The mechanistic data on the anticancer activity of WFA are backed by the
growing body of evidence demonstrating the preclinical efficacy of WFA against
various cancer types in vitro and in vivo. Perhaps the most extensively investigated
type of cancer for which WFA has shown excellent activity is breast cancer. Here,
multiple lines of evidence from independent studies indicate that WFA induces
apoptosis in estrogen-sensitive (MCF-7) and estrogen-independent (MDA-MB231) breast cancer cells in vitro [55]. In the same study, the in vitro findings were
corroborated by in vivo studies in which intraperitoneal administration of WFA (4
mg/kg) in nude mice significantly attenuated the growth of subcutaneous MDAMB-231 xenografts. Similarly, in another study using orthotopically implanted 4T
15

mouse mammary tumor cells, it was reported that intraperitoneal administration of
WFA (0.1, 0.5, 1, 2 and 4 mg/kg body weight) significantly inhibited breast cancer
progression and metastasis in a dose-dependent manner [39, 56]. Furthermore, a
study using a clinically-relevant transgenic animal model for breast cancer in
MMTV-neu mice reported more than 50% inhibition of weight of palpable tumors
following treatment with 100 µg of WFA (3 times/week) for 28 weeks [37, 56].
In addition to breast cancer, the evidence is available to support the efficacy
of WFA against prostate, ovarian, and cervical cancers. For example, in a study
conducted in nude mice, intraperitoneal administration of WFA [4-8 mg/kg/day] for
24 days resulted in over 70% inhibition of PC3 subcutaneous tumor growth [57].
The authors attributed the effects of WFA to inhibition tumor proteasomal activity
and induction of apoptosis in PC3 cells. Similarly, another independent study in
WFA [3 or 5 mg/kg] was administered orally to transgenic mice for 39 weeks, there
was significant inhibition of tumorigenesis and metastasis of prostate
adenocarcinoma [36]. In cervical cancer, data from in vitro and in vivo experiments
indicates the inhibition of human papillomavirus oncogenes E6/E7 coupled with
induction of p53, the tumor suppressor protein [34]. Furthermore, administration of
WFA alone or in combination with cisplatin to nude mice bearing A2780 human
ovarian cancer cell xenografts resulted into 70-80% reduction in tumor growth and
complete inhibition of metastasis [40, 58, 59]. Together, these data demonstrate
the efficacy of WFA against gynecological cancers and further highlight the
potential of WFA as a potential chemotherapeutic agent.
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MATERIALS AND METHODS
Materials
Culture media (1X DMEM and RPMI 1640), 0.25% Trypsin-EDTA, Bolt
MES-running buffers, antibiotics (100 U/mL penicillin/ 100µg/mL streptomycin),
and fetal bovine serum (FBS) were purchased from Life Technologies (Grand
Island, NY). RIPA cell lysis buffer, halt protease/phosphatase inhibitor cocktail,
BCA protein assay kits, PVDF-transfer membranes, ECL chemiluminescence
reagents and the 10-well Bolt 4-12% Bis-Tris phosphate gels were purchased from
ThermoFisher Scientific (Rockford, IL). The tissue culture treated plates (96-well,
24-well, 12-well, and 6-well) and culture treated dishes (60 mm and 100 mm) were
purchased from CytoOne (USA Scientific, FL).
The 2-well culture inserts and the 8-well glass µ-slides were purchased from
ibidiÒ cells in focus (Madison, WI). The transwell tissue culture inserts and the
matrigel base membrane matrix were purchased from Corning (Bedford, MA).
Recombinant human transforming growth factor (hTGFβ-1), primary antibodies
(anti-E-Cadherin, anti-Vimentin, anti-Snail, anti-ZEB1, anti-β-Catenin, anti-β-actin,
anti-slug, anti-Bcl2, anti-Bax, anti-PARP, anti-cyclin E2, anti-cyclin B1 and antiSTAT3) as well as secondary (anti-mouse IgG and anti-rabbit IgG) antibodies were
purchased from Cell Signaling Technology, Inc. (Danvers, MA).
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The FITC-AnnexinV/PI apoptosis assay kits were purchased from Invitrogen
(Eugene, OR), while the phosphate-buffered-saline (PBS) and MTT reagent [3-(4,
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide] were purchased from
Sigma-Aldrich (St. Louis, MO).
Cell lines and culture
Two human NSCLC cell lines, H1299 (p53-null, EGFR-WT) and A549 (p53WT, EGFR-WT), originally purchased from American Type Culture Collection
(Manasa, VA, USA) and sub-cultured in the laboratory were used. These cells
were maintained in monolayers at 70-80% confluence in DMEM supplemented
with 10% heat-inactivated FBS and 1% antibiotics at 37°C in a 5% CO2 humidified
incubator. Culture media was replaced with fresh media every 2 days and cells
were passaged at >80 % confluence.
MTT cell viability assay
Cell viability was indirectly measured by MTT assay as described previously
[60] using the yellow MTT reagent. In this assay, the ability of cells to metabolize
the yellow tetrazolium MTT reagent to purple intracellular formazan crystals in the
mitochondria was used as an indirect measure of cell viability. Briefly, H1299 and
A549 cells (3000 cells/well) in 100µL of DMEM media were seeded in 96-wells
plates and incubated for 24 hours at 37°C in a 5% CO2 incubator. The seeding
culture media was discarded by aspirating into a waste bottle and replaced with
media containing various concentrations of either paclitaxel or WFA or the
combination (1:25 and 1:50) and then incubated further for 72 hours. At the end of
the desired incubation period, culture media was replaced with media containing
18

0.5 mg/mL MTT solution, incubated for an additional 3 hours at 37°C after which
the media was discarded. To solubilize the formazan crystals, 200 µL of dimethyl
sulfoxide (DMSO) was added and the absorbance of the resulting solution was
determined spectrophotometrically at 570 nm.
Apoptosis analysis by flow cytometry
Apoptosis induction was analyzed by detecting phosphatidylserine (PS)
translocation from the inner to the outer leaflet of the plasma membrane [61]. The
calcium-dependent PS-binding protein, Annexin V (35-36 kDa), was used as a
probe to determine the percentage of apoptotic cells after incubation with PAC or
WFA alone and in combination. The FITC-Annexin V/PI cell staining kit (Cat. No.
V13242, Invitrogen) containing a recombinant Annexin V conjugated to fluorescein
(FITC), and propidium iodide (PI), a red fluorescent nucleic acid binding dye was
used. In this assay, apoptotic cells present with PS flipped from the inner to the
outer membrane and as such are bound by the Annexin V protein. Secondly, PI is
impermeable to live cells but stains dead cells with red fluorescence by binding
tightly to nucleic acids.
In the present study, H1299 and A549 cells were seeded in 60 mm culture
plates and cultured to 70% confluence. Prior to incubation with drugs, cells were
serum-starved for 24 hours then cultured in media containing either WFA (0.5 µM)
or PAC (10 nM) or the combination at the respective concentrations for 48 hours.
Following this incubation period, the cells were collected by aspirating the media
and adding 1 mL of 0.25% trypsin-EDTA to each culture plate to detach the cells.
The collected cells were washed twice with ice-cold PBS and suspended in 1x
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Annexin-binding buffer at a cell density of approximately 1 x 106 cells/mL in a total
volume of 100 µL. To each 100 µL of cell suspension, 5 µL of FITC-Annexin V and
1 µL of 100 µg/mL PI solution were added and incubated for 15 minutes at room
temperature in the dark. Each AnnexinV/PI stained cell suspension was then
diluted with 400 µL of 1x Annexin binding buffer and immediately analyzed for
fluorescence using a flow cytometer by measuring the fluorescence emission at
530 nm and >575 nm. Early apoptotic cells showed green fluorescence, dead cells
had red and green fluorescence while live cells showed little fluorescence. A total
of 10,000 cells were counted in each cell suspension and the data expressed as
percentage early and late apoptotic cells.
Cell adhesion assay
The cell adhesion assay was conducted as previously described [62] to
determine the effects of PAC or WFA alone and in combination with the ability of
cells to bind extracellular matrix. Briefly, 96-well plates were pre-coated with 40 μL
of ice-cold 50 μg/mL matrigel solution and stored at 37 °C in a humidified incubator
until used in the experiment. Also, H1299 and A549 cells were cultured in 100-mm
culture dishes and allowed to grow up to 70-80% confluence. The cells were then
serum starved for 24 hours, washed twice with serum-free DMEM media to remove
dead cells and detached from the plates by adding 1 mL of 0.25% trypsin-EDTA.
The collected cells were centrifuged at 350 x g for 5 minutes to remove debris and
counted under the microscope. Cell adhesion assay was conducted by seeding 1
x 104 cells/well in 100 μL of serum free DMEM media (with or without TGFβ1) into
the 96-well matrigel pre-coated plates. To determine the effect of PAC and WFA,
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alone and in combination, at the indicated concentrations on cell adhesion, each
agent was added to the cell suspension before seeding. Following cell seeding,
culture plates were incubated at 37°C and 5% CO2 for 2 hours to allow attachment
of cells to matrigel. Thereafter, non-adherent cells were removed by washing twice
with PBS, then 100 µL of DMEM (10% FBS) was added to each well and the plates
were incubated for an additional 8 to allow recovery of cells. The cell viability of
adherent cells was determined by MTT assay.

Wound healing assay
The effects of PAC and WFA, alone and in combination on motility of H1299
and A549 cells were determined by wound healing assay. This experiment was
performed using the 2-well tissue culture inserts (ibidi® cells in focus) following
manufacturer’s instructions. Briefly, H1299 and A549 cells in DMEM media (10%
FBS) were cultured to 70-80% confluence in 100-mm culture dishes at 37°C and
5% CO2. At 80% confluence, cells were serum starved for 24 hours and collected
by adding 1 mL of 0.25% trypsin-EDTA and centrifuged at 350 x g for 5 minutes to
remove dead cells and debris. Cells were re-suspended in DMEM media, counted
under a light microscope and the cell number was adjusted to 3 x 105 cells/mL.
To each of the 2-well culture inserts, a total of 70 μL the cell suspension (3
x 105 cells/mL) was added and incubated at 37°C and 5% CO2 for 24-hours to
obtain a confluent monolayer of cells in each of the chambers. Thereafter, culture
inserts were removed to expose the wound area (gap) between the two cell growth
areas using a pair of forceps. Floating and dead cells were removed by washing
the cells twice using serum-free DMEM media, then cells cultured in serum-free
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DMEM media containing PAC or WFA alone or the combination. The gap area was
monitored by examining the cells under a light microscope immediately (0-hours)
and after 24 hours post treatment. The percent migration in each microphotograph
was determined using Wimasis Image Analysis software (WimScratch).
Transwell cell migration and invasion assay
The effects of WFA and PAC, alone and in combination on transwell
migration and invasion of human NSCLC cells were determined using 8-μm pore
size transwell culture inserts. Briefly, H1299 or A549 cells (8 x 105 cells/plate) were
cultured in 100-mm culture plates in DMEM media (10% FBS) to 70-80%
confluence. Thereafter, cells were serum starved for 24 hours and detached from
plates using 0.25% trypsin-EDTA, suspended in serum free media and counted.
To conduct the transwell migration assay, 2.5 x 104 cells in 200 μL of serum
free DMEM media (with and without TGFb1 in presence or absence of PAC or
WFA alone and in combination) were seeded in the upper chamber of the transwell
insert. A total of 600 μL of DMEM (10% FBS) was added to the bottom chamber
to act as an attractant to cause cell migration. After 24-hour incubation, the
migrated cells at the bottom of the insert were washed twice with PBS and fixed
using 3.7% paraformaldehyde at room temperature for 10 minutes. The fixed cells
were washed twice using PBS, permeabilized using 100% methanol for 20 minutes
at room temperature and stained using 0.2% toluidine blue (in 1% sodium borate)
for 15 minutes. The non-migrated cells remaining in the upper chamber of the
transwell insert were removed using a cotton swab, and the number of migrated
cells counted under the microscope. In the matrigel invasion assay, the same
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procedure was followed except that the upper chamber of each transwell insert
was pre-coated with 40 μL of 3.0 mg/mL matrigel at 4°C prior to cell culture. The
number of migrated cells for each experimental unit was compared with the
number of migrated cells in the control group.
Western blot analysis
Western blotting was performed to compare expression levels of specific
proteins in H1299 and A549 cells following incubation with either WFA or PAC,
alone and in combination. In each experiment, cells were cultured up to 70-80%
confluency and then incubated with either WFA or PAC, alone and in combination
as indicated. The cells were collected using 0.25% trypsin-EDTA and washed
twice with PBS at 4°C. Whole-cell protein lysates were prepared by suspending
collected cell pellets into 50-100 μL of RIPA buffer and incubated for 30 minutes
on ice. Thereafter, cells were lysed by vortexing the cell suspension for 30 seconds
and protein lysate collected by centrifugation at 17000 x g for 45 minutes. The
supernatant for each sample was transferred into labeled pre-chilled 1 mL tubes
and the total protein concentration for each sample was determined by BCA
method. For detection of specific proteins, volumes containing 20 μg of protein
were loaded and separated per molecular weight on sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) using Bolt electrophoretic
apparatus following manufacturer’s instructions.
Pre-stained proteins (10 μL) were loaded alongside the samples and used
as molecular weight markers on either side of the gel during electrophoresis. The
separated proteins were transferred from the gels onto PVDF membranes using a
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Bio-Rad Transblot Cell apparatus at 20mV for 20 minutes. The membranes were
washed in Tris-buffered-saline containing 0.1% Tween-20 (TBST) buffer for 5
minutes and blocked with 5% non-fat milk prepared using TBST for 1 hour. After 3
wash cycles (5 minutes each) in TBST, blots were cut according to protein
molecular weight and the respective blots were incubated with primary antibodies
in 10 mL of 5% non-fat dry milk (1:1000) at 4° C overnight. The following day, blots
were washed 5 times in TBST (10 minutes each) to remove unbound primary
antibodies and then incubated with respective HRP-conjugated secondary
antibodies in 5% non-fat dry milk (1:3000) for 1 hour at room temperature. The
primary and secondary antibody solutions were collected into 15 mL tubes and
stored at -80°C for use in other experiments. The expression levels of each protein
were determined by visualizing protein bands on blots using ECL detection
reagents (Thermo Scientific) and images for each blot were developed. β-actin (for
total protein) was used as protein loading control in all the experiments.
Data and statistical analysis
In all experiments, vehicle and positive control groups were used to assess
the validity of experimental conditions. Data were presented as means ± SD of
technical replicates from at least 3 separate experiments. Normality and
homogeneity of variances for all data sets were determined before conducting to
one-way ANOVA. Comparisons of experimental versus vehicle control groups
were done using the student's t-test and p-values <0.05 were considered
statistically significant.
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Calculation of synergism between PAC and WFA
The synergistic interaction between PAC and WFA was determined using
the combination index (CI) method developed Chou et al., [63]. In this method, the
fraction affected (fu) and the fraction unaffected were used to represent the
percentage of cells killed by drug and the percentage of viable cells, respectively
at each dose (D). For either PAC or WFA, the relationship between D, fa, fu and Dm
was expressed in the median-effect equation (1) below;

f
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m

D

Equation (1)

D

m

where; m is the shape of the dose-effect curve, and Dm is the median inhibitory
concentration (IC50). Using equation (1), the dose (Dx) of either PAC (i.e. DxPAC) or
WFA (i.e. DxWFA) alone that caused a specific inhibitory effect x% on the individual
dose-response curves could be estimated by rearranging Equation (1) as follows;
Dx

= Dm

f
f

1/m
a

Equation (2)

u

Further, the doses of PAC (DPAC) or WFA (DWFA) in the combination contributing to
the same inhibitory effect (x%) as the individual agents was estimated from the
combination dose-response curves using Equation (2). Equation (1) was further
expressed in the logarithmic form as Equation (3) to enable the calculation of either
Dm or D whenever other values of the equation were known.
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Equation (3)

Synergism at a specific effect levels (e.g. 50%, 75% or 90%) was determined by
calculating the combination index (CI) using Equation (4), that essentially
compared the doses; Dx (drug alone) and D (drug in the combination) for both PAC
and WFA required to produce the same effect.

CI

=

DPAC
DxPAC

+

DWFA

Equation (4)

DxWFA

where; DPAC and DWFA were the doses of PAC and WFA, respectively in the
combination while, DxPAC and DxWFA were the doses of PAC and WFA alone,
respectively at the selected effect level. The CI values; CI<1, C=1 and C>1
indicated synergism, additive and antagonism, respectively. All these calculations
were performed using CalcuSyn Version 2.0 software.
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RESULTS
Antiproliferative activity of PAC and WFA against H1299 and A549 cells
NSCLC cells are reported to be highly proliferative tumor cells that are
usually resistant to standard chemotherapeutic agents. Therefore, targeting cell
proliferation is a therapeutically viable strategy for developing clinically effective
drugs. The objective of the present study was to determine and compare the
effects of PAC and WFA alone, and in combination on the proliferation of two
human adenocarcinoma cell lines, H1299 and A549. Cells were incubated with
PAC or WFA alone and in combination for indicated time points and cell viability
was determined by MTT assay. The hypothesis was that PAC as the standard-ofcare therapeutic, when used in combination with WFA would result into
significantly enhanced antiproliferative activity and/or decrease the concentration
of PAC required to achieve similar or higher anticancer effects. The dose-response
data was used to calculate the median inhibitory concentrations (IC50) of either
PAC or WFA alone and in combination.
Figure 4A depicts the dose-response curves for PAC [0-40 nM] and WFA [0-2000
nM] alone against the proliferation H1299 and A549 NSCLC cells. It was observed
that PAC alone had a dose-dependent inhibitory effect on proliferation of both
H1299 and A549 cells. For the two cell lines, concentrations of PAC alone (less
than 5 nM) displayed similar antiproliferative activities as indicated by the shape of
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the dose-response curve. However, at PAC concentrations of 8 nM and greater,
there was more antiproliferative activity against A549 cells than towards H1299
cells. The IC50 values of PAC were 8 nM and 25 nM against A549 cells and H1299
cells, respectively. Despite the remarkable potency of PAC against either cell lines,
the maximum achievable inhibitory effect (or efficacy) for PAC was less than 80%
for the doses tested in this experiment.
Similarly, WFA also displayed dose-dependent inhibitory antiproliferative
effects against both H1299 and A549 cells. Based on data from the dose-effect
plot approximations, at WFA concentrations less than 800 nM, both H1299, and
A549 cells had similar percent viability. However, as WFA concentrations
increased to 1000 nM and greater, there was a greater antiproliferative activity of
WFA towards H1299 cells than A549 cells. The overall IC50 values of WFA were
831 nM and 683 nM against A549 and H1299 cells, respectively. Unlike PAC, at
the tested concentrations, the efficacy of WFA was greater than 90% against both
cell lines. Together, these results indicated that PAC had higher potency but lower
efficacy than WFA against both cell lines at the tested concentrations.
Based on the results of the antiproliferative activity of PAC and WFA alone,
it was hypothesized that the combination of PAC and WFA would have greater
antiproliferative effects than each agent alone. Initially, both cell lines were
incubated either PAC (10 nM) or WFA (0.5 µM) alone and in combination and the
cell viability was determined at multiple time points. Figure 4B shows the timedependent antiproliferative activity of PAC and WFA at multiple time points.
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Figure 4. Antiproliferative activity of PAC and WFA, alone and in combination against H1299 and
A549 NSCLC cells in vitro. (A) The dose-response effects of PAC and WFA alone against H1299
and A549 cells respectively. The cells were cultured in DMEM media in 96-wells culture plates and
incubated with PAC [0-40 nM] or WFA [0-2000 nM] for 72 hours. The IC50 of PAC were 8.1 and 25
nM while the IC50 for WFA were 831 and 683 nM against A549 and H1299 cells, respectively. (B)
The time-dependent antiproliferative activity of PAC [10 nM] or WFA [0.5 μM] alone and in
combination against A549 and H1299 cells. Both PAC and WFA alone decreased the viability of
cells especially at 48 and 72 hours (*p<0.05). The combination of PAC and WFA had a greater
inhibitory effect than either PAC or WFA alone (**p<0.001). Data are mean ± SD values (n=8).
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WFA synergizes the anticancer effects of PAC against H1299 and A549 cells
To investigate whether the antiproliferative activities of the combination of
PAC and WFA was synergistic, the dose-response data of PAC or WFA alone and
in combination was subjected to synergism analysis using the method described
by Chou et al., [63]. Figure 5A shows the dose-response plots of PAC and WFA
alone and in combination (1:50) against H1299 cells. The results indicate that both
PAC and WFA alone had dose-dependent inhibitory effects on the proliferation of
H1299 cells. Interestingly, for concentrations less than 12 nM, PAC alone
displayed higher inhibitory effects on cell proliferation than WFA. However, the
overall maximum inhibitory effect on cell proliferation was only about 60-70% for
PAC while that of WFA was >90% for concentrations equal or greater than 2 µM.
Together, these results demonstrate that PAC shows higher potency but lower
efficacy than WFA against the proliferation of H1299 cells.
When PAC was combined with WFA, the inhibitory effects on H1299 cell
proliferation was dramatically increased and there was a change in the shape of
the dose-response curve. Figure 5B depicts the CI versus fractional effect plot of
the combination of PAC and WFA at a combinatorial ratio of 1:50, respectively. For
fractional effects between 0.2 and 1.0, the CI values were all below 1 indicating a
synergistic interaction between PAC and WFA. Figure 5C shows the summary of
CI values at IC50, IC75, and IC90 which were 0.8, 0. 8, and 0.8, respectively for the
combinatorial ratio of 1:50. Similarly, at the combinatorial ratio of 1:25, the CI
values at IC50, IC75 and IC90 were 0.8, 0.6, and 0.6 respectively. The overall IC50
values for PAC and WFA combination were 7 and 10 nM at 1:50 and 1:25 ratios.
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Similarly, against A549 cells, as shown in figure 6A, PAC and WFA alone had
dose-dependent inhibitory effects on cell proliferation with maximum effects of 70%
and >80% for PAC and WFA, respectively. The combination of PAC and WFA had
greater dose-dependent inhibitory effects on cell proliferation than each agent
used alone. Moreover, greater than 80% of A549 cell proliferation was achieved
with concentrations of PAC and WFA less than 20 nM and 1 µM, respectively.
Figure 6B shows the CI versus fractional effect plot of the combination of
PAC and WFA at a combinatorial ratio of 1:50. As indicated, there was a dramatic
decrease in the concentration each agent required to achieve specific inhibitory
effects against A549 cells. The combination of PAC and WFA had CI values less
than 1 for fractional effects between 0.2 and 1.0 against both H1299 and A549
cells. This indicated that the interaction of PAC and WFA was synergistic at 1:50
combination ratio. In summary, table 1 indicates that for H1299 cells, the
combination achieved a 3-fold and 4-fold reduction in the IC50 values of PAC when
it was combined with WFA. Moreover, at higher inhibitory effects (75% and 90%),
there was an even greater dose reduction for PAC of up to 8-fold and 17-fold,
respectively. Similarly, in A549 cells, specific inhibitory effects (50%, 75%, and
90%) were achieved with much lower paclitaxel concentrations (3-fold, 12-fold, and
46-fold), respectively.
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Figure 5. The synergistic antiproliferative activity of PAC and WFA against H1299 NSCLC cells.
(A) The percent inhibition versus concentration of PAC or WFA alone and in combination. There
were dose-dependent inhibitory effects for both PAC and WFA on cell proliferation. PAC had a
higher potency than WFA at concentrations lower than 12 nM but the maximum inhibition was
<60% and about 90% for PAC and WFA, respectively. The combination of PAC and WFA (1:50)
had much greater potency and efficacy than either PAC or WFA alone. (B) The CI versus fractional
effect plot shows that CI < 1 for fractional effects 0.2 to 1.0 indicating synergism of PAC and WFA
as calculated by CalcuSyn Software (CI<1). (C) The summary of CI values (<1) at IC50, IC75, and
IC90 indicating synergism between PAC and WFA.
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Figure 6. The synergistic antiproliferative activity of PAC and WFA against A549 NSCLC cells. (A)
The percent inhibition versus concentration plot for PAC or WFA alone and in combination. There
were dose-dependent inhibitory effects for both PAC and WFA on cell proliferation. PAC had a
higher potency than WFA at concentrations lower than 25 nM and a maximum percent inhibition of
70% and about 90% for PAC and WFA, respectively. The combination of PAC and WFA (1:50) had
much greater potency and efficacy than either PAC or WFA alone with maximum percent inhibition
>95% at <10 nM PAC. (B) The CI versus fractional effect plot indicates CI < 1 for fractional effects
0.3 to 1.0 indicating synergism of PAC and WFA as calculated by CalcuSyn Software (CI<1). (C)
Shows the summary of CI values (<1) at IC50, IC75, and IC90 indicating synergism between PAC
and WFA.
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Table 1. Dose reduction of PAC in combination with WFA against NSCLC cells

Dose of PAC (nM)

Cell line

PAC:WFA
(1:0)

PAC: WFA
(1:50)

PAC:WFA
(1:25)

25

5

3

4

50

25

7

10

75

116

15

19

90

544

32

42

25

0.9

0.9

0.9

50

8

2

4

75

74

6

11

90

669

15

26

Effect (%)

H1299

A549
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Effect of PAC and WFA on induction of apoptosis in H1299 and A549 cells
Most anticancer agents including PAC halt the progression of cancer cells
through the induction of apoptosis. To date, several studies have also provided
evidence to show that WFA can induce apoptosis in various cancer cell types
including NSCLC. To investigate whether WFA enhanced the antiproliferative
activity of PAC through increased induction of apoptosis in NSCLC cells, we
compared the percentage of apoptotic cells between PAC and WFA alone and in
combination (1:50). Figure 7A and 7B show the Annexin V/PI dead cell assay
results for cells incubated with either PAC or WFA alone and in combination. PAC
alone increased the percentage of both H1299 and A549 cells positive for Annexin
V stain, an indicator of increased apoptosis, with greater efficacy in A549 cells. On
the other hand, WFA resulted into an increased number of Annexin V positive cells
in H1299 cells more than in A549 cells. The combination of WFA and PAC resulted
in a higher percentage of Annexin V positive cells for both H1299 and A549 cells
than either PAC or WFA alone. The induction of apoptosis was also determined by
western blot analysis of whole-cell lysates for increased levels of cleavage of
PARP, a product of active caspases (Figure 7C).
In figure 8, western blot analysis revealed that WFA increased the levels of
the pro-apoptotic protein Bax while decreasing the levels of the anti-apoptotic
protein Bcl-2. Similarly, cell cycle regulatory proteins (cyclin E and cyclin B) were
significantly decreased, indicating possible cell cycle arrest and induction of
apoptosis. Overall, the combination of PAC and WFA induced apoptosis probably
through cell cycle arrest by inhibiting the expression.
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Figure 7. Effect of PAC and WFA on induction of apoptosis in H1299 and A549 NSCLC cells. (A).
PAC and WFA increased the percentage of AnnexinV positive (apoptotic) cells compared to
controls in both H1299 and A549 cells. PAC had higher activity against A549 cells while WFA had
greater activity against H1299 cells. The combination of PAC and WFA had a significantly
(**p<0.05) induced apoptosis in a higher percentage cells than either PAC or WFA alone (B)
Western blot analysis of whole cell lysates after incubation with PAC and WFA alone, and in
combination indicating increased levels of cleaved-PARP.
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Figure 8. Western blot analysis depicting the effect of PAC and WFA alone and in combination on
regulators of apoptosis and cell cycle. PAC alone had minimal inhibitory effects on the expression
of the mitochondrial anti-apoptotic protein Bcl-2, but WFA had a dose-dependent inhibition of Bcl2 expression. The combination of PAC and WFA significantly decreased the levels of Bcl-2 than
either PAC or WFA alone, indicating greater pro-apoptotic potential. Furthermore, the levels of the
pro-apoptotic protein Bax were minimally affected by PAC alone but increased in response to WFA
alone or in combination with PAC. The cell cycle regulatory proteins Cyclin E2, Cyclin B1 and STAT3
were also minimally affected by PAC compared to controls but were decreased when cells were
incubated with WFA alone and in combination with PAC. β-actin was used as total protein loading
control.
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Effect of PAC and WFA on the migration of H1299 and A549 cells.
The migratory capacity of NSCLC cells is a key molecular event in the ability
of primary tumors to establish distant metastases. Therefore, we investigated the
anti-migratory effects of PAC and WFA alone and in combination against H1299
and A549 cells. The wound healing assay was performed and used to determine
the rate of migration or motility of both H1299 or A549 cells over 24 hours in the
presence of PAC (10 nM) or WFA (0.5 µM) alone and in combination.
Figure 9 shows the migration of H1299 cells over a 24-hour experimental in
cell culture. The results indicate that H1299 cells cultured in DMEM alone (vehicle)
achieved almost 100% migration into the cell gap at 24 hours. In the presence of
PAC alone, a minimal effect on H1299 cell migration (>80% migration) compared
to the migration in control wells was observed. In contrast, in the presence of WFA,
there was a statistically significant (*p<0.05) inhibitory effect on cell migration
(<70% migration). Furthermore, when cells were incubated with the combination
of PAC and WFA, the anti-migratory effects were dramatically enhanced and even
greater inhibition (#p<0.05 versus WFA alone) of H1299 cell migration (<50%
migration). Figure 10 shows the wound healing assay for the migration of A549
cells depicting up to 50% and 60% inhibition of A549 cell migration for PAC and
WFA, respectively. As was observed for H1299 cells, the combination of PAC and
WFA had a significantly (#p<0.05 versus WFA) greater inhibitory effects on the
migratory capacity of both H1299 and A549 NSCLC cells compared to either PAC
or WFA alone.
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Figure 9. Wound healing assay depicting migration of H1299 NSCLC cells. The area
covered with cells is indicated in green and was compared between time 0 and 24 h to
determine percent migration. The control group of cells, cultured in media alone had
increased migratory capacity (>99%) within 24 hours. PAC (10 nM) had minimal effect on
H1299 cell migration (80-90% migration) which was not statistically significant. However,
incubation of cells with WFA (0.5 µM) alone significantly (*p<0.05) inhibited the cell
migration compared to control. Further, H1299 cells incubated in media containing a
combination of PAC and WFA (1:50) significantly inhibited the migration of cells in the gap
area greater than either PAC or WFA alone (*p<0.05 versus control, and #p<0.05 versus
either PAC of WFA alone). Data are mean±SD of 3 experiments.
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Figure 10. Wound healing assay depicting migration of A549 NSCLC cells. The area covered with
cells is indicated in green and was compared between time 0 and 24 h to determine percent
migration. The control group of cells, cultured in media alone had increased migratory capacity (8095%) within 24 hours. A549 cells incubated with PAC (10 nM) alone had decreased percent
migration (<60%) which were statistically significant (*p<0.05) compared to control group of cells.
Further, WFA (0.5 µM) alone significantly (*p<0.05 versus control, #p<0.05 versus PAC alone)
inhibited A549 cell migration. The combination of PAC and WFA (1:50) resulted into much lower
percent migration (<40%) that was statistically significant compared to either PAC or WFA alone
(##p<0.05 versus either PAC of WFA alone). Data are mean±SD of 3 experiments.
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Effect of PAC and WFA on TGFβ1-induced EMT in H1299 and A549 cells
Epithelial-to-mesenchymal transition (EMT) is set of complex cellular events
which cancer cells undergo to transition from an epithelial to a mesenchymal
phenotype. This process enhances the migratory capacity of cells and increases
the chance of metastasis. To investigate whether WFA alone or in combination
with PAC inhibited TGFβ1-induced EMT in H1299 and A549 cells, we compared
the cellular morphology and the expression levels of known molecular markers of
mesenchyme phenotype between cells cultured with PAC and WFA, alone and the
combination.
Figure 11 shows that A549 cells cultured in serum-free media had visible
cell-cell contact, and a rounded cell shape typical for that cell line. However, the
incubation of these cells with 5 ng/mL TGFb1 in serum-free media, cells caused
significant changes in cell morphology characteristic of the transition from an
epithelial to mesenchymal phenotype. To corroborate these findings, western blot
analysis (Figure 12) of whole-cell lysates of A549 and H1299 cells following
incubation with 5 ng/mL of TGFb1 with or without PAC or WFA alone and in
combination was performed. The results indicate that TGFβ1 induced the
expression of EMT markers, vimentin, β-catenin, Snail, and ZEB while decreasing
the levels of the epithelial marker E-cadherin in either A549 or H1299 cells.
Together, the morphology changes and EMT protein expression was considered
a positive change of the cells from an epithelial to mesenchymal phenotype. For
both cell lines, PAC had minimal effects on the TGFβ-induced EMT markers within
the experimental period of 24 hours. In contrast, in the presence of WFA alone,
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there was significant inhibition of the expression of EMT markers in both cell lines.
There was a dose-dependent inhibition of vimentin, β-catenin, Snail, and ZEB
expression when cells were incubated with WFA alongside TGFb1. Furthermore,
for both NSCLC cell lines, the observed TGFβ1-induced downregulation of Ecadherin was also inhibited when cells were incubated in the presence of WFA.
The combination of PAC and WFA had an even greater inhibitory effect on TGFβ1 induced EMT in A549 and H1299 cells. Based on these findings, we explored
the ability of PAC and WFA to inhibit adhesion and migration induced by TGFβ1.
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Figure 11. Immunofluorescence staining depicting the effect of PAC and WFA on TGFβ1-induced
morphological changes in A549 cells. Cells were cultured in 8-well µ-slides, serum starved for 24
prior to the treatment and incubated with 5 ng/mL TGFβ1 in serum-free media for an additional 24
hours. WFA alone, and in combination with PAC inhibited the morphological changes induced by
TGFβ1.
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Figure 12. Western-blot analysis depicting the effect of PAC and WFA on TGFβ1-induced EMT in
A549 cells cultured for 24 hours. Cells cultured in serum-free media alone had minimal expression
of EMT markers. However, A549 and H1299 cells cultured in serum-free media containing TGFβ1
(5 ng/mL) had an increased expression of EMT protein markers, vimentin, and β-catenin as well as
transcription factors ZEB and Snail but decreased levels of the protein E-Cadherin. WFA, alone
and in combination with PAC, inhibited the TGFβ1-induced EMT in both cell types. β-actin was
used as an internal loading control.
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Effect of PAC and WFA on TGFβ1-induced adhesion of H1299 and A549 cells
Cell adhesion refers to the ability of cells to bind to an extracellular matrix
or other cells. This process involves complex biochemical changes in the cells that
result in the expression of specific molecules on the surface of the cell and it is
important for cell-cell communication, growth, and survival of cells. Through cell
adhesion, circulating tumor cells can establish distant metastases by attaching to
distant tissues. Therefore, we investigated whether WFA and PAC alone and in
combination could inhibit TGFβ1-induced adhesion of H1299 and A549 cells.
Figures 13 and 14 show the findings from the cell adhesion assay for A549
and H1299 cells, respectively. In each case, the OD values from cells cultured in
serum-free media were presented as 100% cell viability and used as a reference
to calculate the fold change in adhesion when cells were cultured in serum-free
media containing TGFb1. In figure 12, A549 cells cultured in serum free media
containing 5 ng/mL of TGFβ1 had significantly (*p < 0.05) higher (4-fold) percent
adhesion to matrigel compared to A549 cells cultured in serum-free media alone
(control). However, when A549 cells were incubated with TGFb1 in the presence
of PAC [12-100 nM] alone, there was a dose-dependent decrease in percent cell
adhesion compared to cells that were cultured with TGFb1 alone (**p<0.05 for
PAC+TGFb1 versus TGFb1). Similarly, A549 cells seeded in media containing
TGFb1 and WFA [0.6-5.0 nM] alone had a statistically significant (**p<0.05 for
WFA+TGFb1 versus TGFb1) dose-dependent reduction in percent cell adhesion
compared to cells cultured in the presence of TGFb1 alone. However, when PAC
and WFA were combined (at 1:50 ratio, respectively), the dose-dependent
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decrease in percent A549 cell adhesion was significantly enhanced than when
either PAC or WFA when used alone.
Figure 14 shows the results of the cell adhesion assay depicting the
inhibitory effects of PAC or WFA alone and in combination against TGFb1-induced
H1299 cell adhesion. As was the case for A549 cells in figure 13, the viability of
H1299 cells cultured in serum-free media was considered as 100% adhesion.
When H1299 cells were incubated in serum-free media containing 5 ng/mL of
TGFb, there was a 2-fold increase in H1299 cell adhesion compared to H1299
cells that were incubated in serum free media without TGFb1. Further, both PAC
and WFA alone had statistically significant (**p<0.05) dose-dependent inhibitory
effects on H1299 cell adhesion induced by TGFb1. Interestingly, at the indicated
concentrations, WFA alone had a greater inhibitory effect on cell adhesion than
PAC alone but the combination of the two had greater inhibitory effects on cell
adhesion than the individual agents alone. Together, these data suggest that
combination of PAC and WFA can significantly inhibit adhesion of NSCLC cells to
matrigel in vitro which suggests the ability to inhibit metastasis in vivo.
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Figure 13. Effect of PAC and WFA, alone and in combination, on TGFβ1-induced adhesion of A549
NSCLC cells to matrigel. The figure shows that TGFβ1 (5 ng/mL) significantly (*p<0.05) increased
the adhesion of A549 (4-fold) compared to cells cultured in serum-free media alone (control).
However, either PAC or WFA alone had a statistically significant dose-dependent inhibitory effect
(WFA>PAC) on TGFβ1-induced adhesion of A549 cells to matrigel (**p<0.05 compared to TGFb1
alone). The combination of PAC and WFA had an even greater inhibitory effect on TGFβ1-induced
adhesion of cells than either PAC or WFA alone. Data are percent (Mean ± SD) of controls.
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Figure 14. Effect of PAC and WFA, alone and in combination, on TGFβ1-induced adhesion of
H1299 NSCLC cells to matrigel. The figure shows that TGFβ1 (5 ng/mL) significantly (*p<0.05)
increased the adhesion of H1299 cells (2-fold) compared to cells cultured in serum-free media
alone (control). In contrast, either PAC or WFA alone had a statistically significant dose-dependent
inhibitory effect (WFA>PAC) on TGFβ1-induced adhesion of H1299 cells to matrigel (**p<0.05
compared to TGFb1 alone). The combination of PAC and WFA had an even greater inhibitory effect
on TGFβ1-induced adhesion of cells than either PAC or WFA alone. Data are percent (Mean ± SD)
of controls.
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Effect of PAC and WFA on TGFβ1-induced migration of H1299 and A549 cells
The objective of this study was to determine whether WFA or PAC alone or
in combination could inhibit TGFβ1-induced migration of A549 and H1299 NSCLC
cells. The wound healing assay was performed to mimic the in vitro migration of
H1299 and A549 cells using cell culture inserts in serum-free media. Cell motility
was monitored using a microscope at 0 hours and at 24 hours to determine the
extent of cell migration in serum free media containing 5 ng/mL of TGFb1 in the
presence of either PAC or WFA alone and in combination.
Figure 15 shows that H1299 cells cultured in serum-free media without
TGFb1 (control) had minimal migration (<5%) between 0 and 24 hours. However,
in the presence of 5 ng/mL of TGFβ1, H1299 cells had significantly (*p<0.05)
increased migratory capacity (>80%) compared to the controls within 24 hours.
However, as was observed for the cell adhesion assay, PAC alone (20 nM) had a
statistically significant (#p<0.05) inhibitory effect on TGFb1-induced migration of
H1299 cells compared to H1299 cells cultured with TGFβ1 alone. Thus, there was
only 50% migration into the cell gap when H1299 cells were incubated with PAC
alongside TGFb1 in serum-free media. Similarly, in the presence of WFA (1 µM)
alone, there was less than 20% migration of H1299 cells into the cell gap which
was statistically significantly (#p<0.05) lower than H1299 cells cultured with TGFb1
alone. When H1299 cells were cultured in media containing TGFb1 in the presence
of both PAC and WFA, the percent migration was less than 10% and statistically
different from either PAC or WFA alone (##p<0.0.001).
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Figure 16 depicts the effect of PAC or WFA alone and in combination on the
migration of A549 cells induced by TGFb1 in serum-free media. The figure shows
that A549 cells cultured in serum-free media had minimal migration (10-20%)
between 0 and 24 hours. As was observed with H1299 cells in figure 14, by cotreatment, PAC alone significantly inhibited the TGFb1-induced migration of A549
cells. Furthermore, WFA alone also inhibited TGFβ1-induced cell migration of
A549 but with greater efficacy than PAC. However, the combination of PAC and
WFA had significantly lower percent (<5%) migration of A549 cells than either PAC
or WFA alone, indicating much greater inhibition of cell motility. Together, these
findings indicated that both PAC and WFA alone had inhibitory effects on H1299
and A549 migration induced by TGFb1 in serum-free media and that the inhibitory
effects were enhanced when PAC was used together with WFA.
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Figure 15. Inhibition of TGF-β1-induced migration in H1299 cells. The figure depicts minimal
migration of H1299 cells cultured in serum-free media. However, TGF-β1 (5 ng/mL) in serum-free
media increased the migration of H1299 cells into the scratch area within 24-hours (**p<0.05). Also,
PAC (10 nM) and WFA (0.5 μM) significantly inhibited (WFA>PAC) the TGF-β1-induced migration
of H1299 cells (## p<0.05 vs TGFβ1). The PAC and WFA had a greater inhibitory effect induced
migration of A549 cells in vitro than each agent alone (### p<0.001 vs. PAC and WFA alone).
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Figure 16. Inhibition of TGF-β1-induced migration in A549 cells. The figure depicts minimal
migration of A549 cells cultured in serum-free media. Incubation of cells with TGF-β1 (5 ng/mL) in
serum-free media increased the migratory capacity into the scratch area within 24-hours (**p<0.05).
PAC (10 nM) and WFA (0.5 μM) significantly inhibited (WFA>PAC) the TGF-β1 induced migration
(## p<0.05 vs. TGFβ1). The c of PAC and WFA had a greater inhibitory effect on TGF-β1-induced
migration of A549 cells in vitro than each agent alone (### p<0.001 vs. PAC and WFA alone).
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Effect of PAC and WFA on TGFβ1-induced transwell migration and invasion
of H1299 and A549 cells
The objective of this study was to determine whether PAC or WFA alone
and in combination inhibited the migration of H1299 or A549 cells from the upper
to bottom chamber in a transwell plate. Cells were cultured in serum-free media in
the upper chamber and media containing serum was placed at the bottom as a
chemoattractant. The results are presented as microphotographs of migrated cells
at the bottom of the transwell plate stained with toluidine blue dye after 24 hours.
Figure 17 shows the results of the transwell migration assay while figure 18
shows findings from the matrigel invasion assay. Here, the migration assay
indicated that both A549 and H1299 cells, when cultured in serum-free media, had
minimal migration to bottom chamber of the transwell plates. However, in the
presence of TGFβ1, there was a remarkable and statistically significant increase
in the number of cells that migrated. When cells were co-cultured with TGFb1 and
PAC alone, there was a decrease in the number of migrated cells when compared
to TGFb1 alone. The effect of PAC alone on TGFb1-induced migration was greater
for A549 cells than was observed in H1299 cells. Similarly, when H1299 or A549
cells were cultured with TGFb1 and WFA alone, there was a significant decrease
in the number of cells that migrated to the bottom of the transwell plate.
Interestingly, unlike what was observed with PAC, the effect of WFA was more
pronounced against H1299 than A549 cells. As was observed with other assays,
the combination of WFA and PAC had much greater inhibition of TGFb1-induced
migration of either H1299 or A549 cells compared with each agent alone.
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Figure 18 shows the findings from the in vitro invasion of matrigel assay, a
widely-used method to determine the anti-invasive activity of anticancer agents.
Here, it was clear that serum-starved H1299 or A549 NSCLC cells cultured in
serum-free media had minimal invasion as indicated by the lower number of
stained cells at the bottom of the transwell chamber. However, the invasion of both
cell lines was greatly increased in the presence of 5 ng/mL of TGFβ1 in serumfree media. As was observed with the transwell migration assay, similar effects of
PAC and WFA alone, when co-cultures alongside TGFβ1 significantly decreased
the invasiveness of cells. Further, that the combination of PAC and WFA had a
significantly higher inhibitory effect on cell invasion than when both agents were
used alone. Together, the findings presented from these two assays provided
credence to our hypothesis that PAC and WFA, when used in combination would
produce significantly greater inhibition of migration and invasion of NSCLC cells.
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Figure 17. Inhibitory effects of PAC and WFA, alone and in combination, on TGF-β1-induced transwell migration of A549 and H1299 cells. In control wells, cells grown in serum-free media had
minimal migratory. However, TGFβ1 (5 ng/mL) significantly (*p<0.05) increased the migration of
both A549 and H1299 cells. Further, PAC (20 nM) alone had a statistically significant inhibitory
effect on TGFβ1-induced migration (#p<0.05 vs TGFβ1), but still greater than vehicle (*p<0.05 vs
vehicle). However, WFA (1 μM) alone and in combination with PAC (20 nM) significantly decreased
the number of migratory cells for both A549 and H1299 cell lines compared to TGFβ1 (#p<0.05)
and the vehicle control. Data are means ±SD for each group from 3 independent experiments.
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Figure 18. The inhibitory effects of PAC and WFA, alone and in combination, on TGF-β1-induced
Matrigel base membrane invasion of A549 and H1299 cells. Either A549 or H1299 cells grown in
serum-free media (vehicle) had a minimal number of invasive cells. Incubation of cells with TGFβ1
(5 ng/mL) significantly (*p<0.05) increased the invasion of both A549 and H1299 cells. PAC (20
nM) alone had a inhibited the invasion of cells in response to TGFβ1 (#p<0.05 vs TGFβ1. Similarly,
WFA (1 μM) alone inhibited (much greater than PAC) the invasive capacity of either A549 or H1299
cells induced by TGFβ1. The combination of WFA and PAC also significantly decreased the
number of migratory cells but not much greater than WFA alone. Data are means ±SD for each
group from 3 independent experiments.
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DISCUSSION
Lung cancer remains the leading cause of cancer-related deaths among both
men and women in the U.S and worldwide [1, 2, 7]. Currently, the overall 5-year
survival rate for all stages hovers around 17% while it is only 4% for those who are
diagnosed with advanced disease [1, 3]. Despite improvements in imaging and
diagnostic techniques as well as recent advances in chemotherapy, the prognosis
of lung cancer has remained extremely poor. To date, 60- 70% of lung cancer
patients are diagnosed when the tumors are at advanced stages [2]. For such
patients, the tumors are not amenable to curative surgery due to metastasis, and
the therapeutic objective is not to cure but to manage symptoms and prolong the
lives of patients [13, 18, 23]. Therefore, chemotherapy, targeted or immunotherapy
alone or in combination are the cornerstone of lung cancer treatment [12, 23].
Currently, several drugs are approved for the treatment of advanced NSCLC
but the platinum drugs (either carboplatin or cisplatin) in combination with PAC are
the most widely used as first-line regimens [6]. PAC or taxol, a member of the
taxanes was first approved by FDA for the treatment of NSCLC in 1999 [64].
Mechanistically, PAC acts by binding to β-tubulin and stabilizing microtubules
during cell division causing mitotic arrest [64]. Whether cells undergo apoptosis or
not following mitotic arrest by PAC is dependent on efficient mitotic checkpoint
mechanisms which are often dysregulated in NSCLC cells. Consequently, the
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the response rate of NSCLC to the platinum drugs-PAC regimen is only up to 25%
and clinical efficacy has plateaued at about 10-14 months [6, 18]. Further, the
clinical efficacy of PAC is limited by its poor solubility, drug resistance and doselimiting life-threatening toxicity [13]. To overcome the challenges with cytotoxic
compounds like PAC, targeted therapies and immune checkpoint inhibitors have
been developed and approved for NSCLC treatment. However, even with these
drugs, it is widely reported that only 60% of NSCLC tumors show targetable
mutations and only 25% of patients benefit from immunotherapy [25]. Therefore,
there is an unmet need to develop safe and efficacious drugs for the treatment of
advanced lung cancer.
In the present study, a novel strategy aimed at improving the clinical
efficacy, delay drug resistance and decrease the toxicity of PAC against NSCLC
was explored. This strategy has been explored elsewhere [28] and the effects of
combining standard chemotherapeutic agents with novel non-toxic plant-derived
anticancer compounds against various cancer types are being investigated.
Presently, we focused on WFA because it is one of the most promising plantderived lead anticancer compounds with the potential to become a clinically useful
drug. Over the past decade or so, preclinical data has accumulated indicating the
potency and efficacy of WFA against various cancer cell types. A review of the
literature shows that several studies have been published demonstrating the in
vitro and in vivo efficacy of WFA against the proliferation of various cancer cell
types [37, 39, 65-67]. More importantly, the evidence is now accumulating
indicating the potential of WFA to synergize the anticancer activity of standard
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chemotherapeutic drugs like cisplatin and carboplatin against ovarian and breast
cancers [40].
Building on the hypotheses from previous studies, the present study was
designed to determine the effect of PAC and WFA, alone and in combination, on
the proliferation, migration, and invasion of lung cancer cells. Here we
demonstrated that by combining PAC and WFA, we could effectively target the
proliferation of NSCLC cells and enhance the anticancer activity of PAC. The
strategy of targeting cell proliferation has been reported to be a viable option for
inhibiting NSCLC tumor progression and that it can provide valuable insights into
the clinical efficacy of drug candidates [10]. Like the present study, several other
published studies have also demonstrated the antiproliferative effects of WFA [37,
65, 68] against multiple cancer cell types. The MTT assay was used as an indirect
measure of cell proliferation to demonstrate that WFA significantly enhanced the
antiproliferative activity of PAC against both H1299 and A549 NSCLC cells.
Comparatively, higher (>90% inhibition) antiproliferative activities of PAC were
achievable by co-treatment with WFA.
From the present data, it was evident that both PAC and WFA displayed
time and concentration dependent inhibition of NSCLC cell proliferation. In support
of Weaver et al., [64], the median inhibitory concentrations of PAC were between
8-25 nM, concentrations which were previously reported to be clinically relevant.
Furthermore, the potency of PAC was greater against A549 cells (3-fold lower IC50)
than was observed in H1299 cells. On the other hand, the IC50 values for WFA
against both A549 and H1299 were in the sub-micro molar range indicating the
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greater potency of PAC than WFA. Unfortunately, despite the high potency
displayed by PAC compared to WFA, the overall efficacy of PAC against both cell
lines was less than that for WFA. Therefore, the rationale was to combine the
higher potency PAC and high efficacy WFA to achieve greater activity in the
combination.
The combination strategy of PAC and WFA is justified because more than
one cytotoxic drug combinations are the norm of cancer chemotherapy. However,
determining synergism in a clinical scenario is not practical because it is rare to
study dose-response relationships in patients. Therefore, the current in vitro cell
culture studies provides a useful starting point for investigating the utility of this
drug combination clinically. Using the CI and fractional-effect method developed
by Chou et al., [63] we demonstrated synergism between PAC and WFA against
NSCLC cells. By calculating the CI values at various effect levels, the combination
of PAC and WFA at constant ratios of 1:50 and 1:25 ratios displayed a synergistic
(CI<1) antiproliferative activity against H1299 and A549 cells.
Like the present findings, a synergistic effect of the combination of WFA and
cisplatin against ovarian cancer have been demonstrated previously [40]. In the
present study, for both H1299 and A549 NSCLC cell lines, synergism (C<1) of the
PAC and WFA was observed at effect levels between 25-90%. It was possible to
significantly decrease the amount of either PAC or WFA required to achieve similar
or higher antiproliferative activity. For example, the combination of PAC and WFA
resulted in a 4-fold and a 2-fold decrease in the IC50 values of PAC at 1:50 and
1:25 combinatorial ratios, respectively than PAC alone. Further, it appears that the
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dose reduction was dependent on the effect level and as indicated, there was
greater dose reduction for PAC at 75% and 90% inhibitory effects, respectively.
This dose reduction if can be validated using in vivo models can be exploited
clinically to address the dose-limiting toxicity problems of PAC.
The synergistic effects discussed thus far were based on cell viability
findings from MTT studies. Unfortunately, it is widely reported that MTT assay has
major drawbacks including changes in cellular metabolic and energy processes,
enzyme activity, and uptake of the MTT reagent into cells which could significantly
affect the rate of metabolism of the MTT reagent. We recognized that these factors
could lead to an over/underestimation of cell viability as reported by Wang et al.,
[69]. Therefore, to validate the MTT findings, the ability of PAC and WFA to induce
apoptosis was also assessed. Mechanistically, the induction of apoptosis in cancer
cells is the major mode of action for several cytotoxic anticancer agents [6, 16].
PAC is a potent inducer of apoptosis in many normal and cancer cell types, but,
as noted earlier, the induction of apoptosis by PAC is both time and concentration
dependent [64]. This is because sufficient time is required to allow effective
concentrations of PAC to build up in cancer cells. Unfortunately, NSCLC cells are
reported to have alternative survival pathways that enable progression of the cell
cycle with poorly separated chromosomes. For this and other reasons, cytotoxic
agents like PAC rarely achieve high efficacy levels at tolerable doses [6].
In the present study, PAC-induced apoptosis with greater potency in A549
cells than H1299 cells. On the other hand, WFA significantly induced apoptosis
with greater potency against H1299 than A549 cells. As was observed with MTT
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assay, the combination of PAC and WFA had a greater pro-apoptotic effect than
either PAC or WFA alone. Interestingly, it appears that PAC and WFA induce
apoptosis via distinct anticancer mechanisms making their combination viable and
attractive [44]. There are two main apoptosis pathways-the extrinsic (via cell death
receptors) or intrinsic (mitochondrial) pathways. Our data suggests that PAC,
unlike WFA, had minimal effects on mitochondrial apoptosis regulators Bax and
Bcl-2. For both compounds, there was an inhibitory effect on cell cycle regulatory
proteins. Overall, these findings obtained from the apoptosis assay support the
synergistic interaction of PAC and WFA and suggest that the increased
antiproliferative activity of the combination was dependent on increased induction
of apoptosis in both cell lines.
Metastasis remains the primary cause of death in lung cancer patients yet
there are no approved drugs that specifically target this process [12]. Several
published studies have indicated that mesenchymal characteristics enhance the
migratory and invasive capacities of NSCLC cells during metastatic [70]. Further,
that the tumor microenvironment consists of several cell types including immune
cells, fibroblasts, and vascular cells which produce several factors including
transforming growth factor (TGFβ1). In response to TGFb1, NSCLC cells undergo
complex biochemical changes that enable the transition of the cells from an
epithelial to mesenchymal phenotype [71]. Through, EMT, cells lose cell to cell
contacts, epithelial markers like E-Cadherin, and acquire mesenchymal markers
like vimentin [70].
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Normally, EMT is a beneficial cellular event in various physiological
processes such as wound healing and embryogenesis [70], but in cancer cells,
EMT is associated with cancer metastasis and resistance to chemotherapeutic
agents like PAC [72]. At the molecular level, EMT is activated by signaling
pathways that activate transcriptional factors like Snail, ZEB1, ZO-1, Smad2/3 and
Twist [73]. Multiple lines of evidence now suggest that although TGFβ1 inhibits
tumors in the early stages of carcinogenesis, it is also the most common inducer
of EMT in NSCLC cells [73]. The overall result is that the EMT process increases
metastatic potential of tumor cells. Therefore, we investigated whether PAC and
WFA alone and in combination could inhibit the TGFb1-induced EMT, migration,
invasion and adhesion of H1299 and A549 cells.
In agreement with previous studies [62, 74], we successfully used 5 ng/mL
TGFβ1 in serum-free media to induce EMT in H1299 and A549 NSCLC cells. Our
findings indicate the TGFβ1 decreased the expression of E-cadherin in both A549
and H1299 cells. Also, the cells incubated with TGFβ1 alone had increased levels
of vimentin, β-catenin, Snail and ZEB1. Together, the increased expression of EMT
proteins coupled with repression E-cadherin was used as an indicator of a
transition from an epithelial to a mesenchymal phenotype. However, in the
presence of WFA alone or in combination with PAC, the expression EMT markers
was inhibited. Interestingly, the inhibitory effects of WFA on TGFb1-induced EMT
were observed at sub-cytotoxic concentrations for the incubation period of 24
hours. Based on the present findings, it was not determined whether the inhibitory
effects of WFA were related to decreased synthesis or increased degradation of
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these specific proteins. But as per findings from previous studies conducted with
breast cancer cells [39], it was hypothesized that the observed low expression
levels of vimentin could be related to direct binding of WFA to vimentin and causing
its degradation. Nevertheless, the mechanisms of action of WFA related to its
inhibition of the expression of EMT proteins remain to be determined.
To mimic metastasis in vitro, the cell adhesion assay, migration and invasion
assays were also performed. Cell adhesion is defined as the binding of cells to an
extracellular matrix or other cells and is important for the cell to cell communication
and growth. Increased cell adhesion of NSCLC can be an indicator of enhanced
the ability of cells to establish distant metastases. In agreement with the findings
of Wang et al., [62], TGFβ1 increased cell adhesion, motility, migration, and
invasion of both A549 and H1299 cells. The increased adhesion of H1299 and
A549 cells to matrigel in response to TGFb1 were inhibited by either PAC or WFA
alone and the combination had a much greater inhibitory effect. Similarly, the
migratory and invasive capacities of H1299 and A549 cells were increased by
TGFβ1. Together, the findings from these assays demonstrate the potential of
WFA alone and in combination with PAC as an anti-metastatic regimen for NSCLC.
Therefore, the presented data indicates that PAC and WFA not only inhibited
NSCLC cell proliferation but also inhibited their migration, invasion and cell
adhesion. Moreover, the inhibitory effects of the two agents in combination were
found to be synergistic. As preliminary findings, the current results highlight the
potential of the PAC-WFA combination against NSCLC in humans. However, there
is need to replicate the experiments in appropriate animals models.
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SUMMARY AND CONCLUSIONS
PAC alongside platinum-based drugs is the mainstay for advanced NSCLC
because these tumors are not amenable to curative surgery due to metastasis.
However, this treatment regimen has reached the plateau of clinical efficacy due
to organ toxicity, drug resistance, efficacy and solubility problems. In the present
study, we explored a simple but effective strategy of combining WFA, a novel plantderived anticancer with PAC to increase efficacy and decrease toxicity. The results
presented here demonstrate that WFA synergistically interacted with PAC to inhibit
the proliferation, cell adhesion, migration and invasion of H1299 and A549 NSCLC
cells. Although PAC displayed higher potency than WFA, the overall efficacy was
lower than that of WFA against either H1299 or A549 cells. However, when PAC
and WFA were combined, the potency and efficacy of the combination were
enhanced and significant dose reductions for PAC and WFA were achieved. The
observed synergistic antiproliferative effects of PAC and WFA were attributed to
increased induction of apoptosis in both H1299 and A549 cells. Furthermore, the
synergism displayed here by the combination of PAC and WFA may be explained
in part, because the two agents are known to act via distinct mechanisms. In
conclusion, present data demonstrates the potential of WFA alone and in
combination with PAC against NSCLC. Therefore, there is great promise of clinical
efficacy that can be explored for advanced metastatic NSCLC.
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